Search research articles
Contact Us
Filters
Showing results (131-140 of 143) with videos related to
Page
of 15
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 16, 2011
Hodgkin lymphoma
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W Press, Hongli Li, Heiko Schöder, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2012
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Blood Cancer Discovery
|
February 1, 2023
Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
Francesco Maura, Bachisio Ziccheddu, Jenny Z Xiang, et al.
Blood
|
July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Anita Kumar, Carla Casulo, Joachim Yahalom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma
Anita Kumar, Carla Casulo, Ranjana H Advani, et al.
Blood Cancer Journal
|
June 14, 2018
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
Andrew M Intlekofer, Erel Joffe, Connie L Batlevi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Jacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 13, 2015
Hodgkin lymphoma, version 2.2015
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 11, 2018
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 143) with videos related to
Sort By:
Page
of 15
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 16, 2011
Hodgkin lymphoma
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W Press, Hongli Li, Heiko Schöder, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2012
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Blood Cancer Discovery
|
February 1, 2023
Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
Francesco Maura, Bachisio Ziccheddu, Jenny Z Xiang, et al.
Blood
|
July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Anita Kumar, Carla Casulo, Joachim Yahalom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma
Anita Kumar, Carla Casulo, Ranjana H Advani, et al.
Blood Cancer Journal
|
June 14, 2018
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
Andrew M Intlekofer, Erel Joffe, Connie L Batlevi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Jacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 13, 2015
Hodgkin lymphoma, version 2.2015
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 11, 2018
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Page
of 15